{"filing":{"accession_number":"0001601830-26-000080","cik":"0001601830","ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"rxrx-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000080/rxrx-20260617.htm"},"events":[{"id":11972,"run_id":10535,"accession_number":"0001601830-26-000080","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Recursion Pharmaceuticals' 2026 annual meeting of stockholders held on June 17, 2026. The filing presents voting results for three proposals: election of Class II directors (Najat Khan and Franziska Michor), advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. These are routine but material shareholder votes that affect corporate governance and audit oversight.","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8699,"accession_number":"0001601830-26-000080","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Recursion Pharmaceuticals' 2026 annual meeting of stockholders held on June 17, 2026. The filing presents voting results for three proposals: election of Class II directors (Najat Khan and Franziska Michor), advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. These are routine but material shareholder votes that affect corporate governance and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:05:11.339080+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8699,"accession_number":"0001601830-26-000080","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Recursion Pharmaceuticals' 2026 annual meeting of stockholders held on June 17, 2026. The filing presents voting results for three proposals: election of Class II directors (Najat Khan and Franziska Michor), advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. These are routine but material shareholder votes that affect corporate governance and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:05:11.339080+00:00","company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","filing_date":"2026-06-18"}]}